Tyra director receives 13,160 stock options

Tyra Biosciences director Adele M. Gulfo received a stock option grant for 13,160 shares of common stock at an exercise price of $32.68 per share.

Rhea-AI Filing Summary

Tyra Biosciences director Adele M. Gulfo received a stock option grant for 13,160 shares of common stock at an exercise price of $32.68 per share. This award was issued under the company’s Non-Employee Director Compensation Program and represents compensation rather than an open-market purchase.

The option vests over time: one-twelfth of the shares vest monthly after the May 28, 2026 grant date. If the next annual shareholder meeting occurs before the first anniversary of the grant, any remaining unvested portion will vest on that meeting date, provided she continues serving the company through each vesting date.

Insider Trade Summary

Grant/Award: 13,160 shares

Grant/Award 1 txn

Insider Gulfo Adele M.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	13,160	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 13,160 contracts (Direct)

Footnotes (1)

1. F1. The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Key Figures

Option grant size: 13,160 shares Exercise price: $32.68 per share Underlying common shares: 13,160 shares +2 more

5 metrics

Option grant size 13,160 shares Stock Option (Right to Buy) granted May 28, 2026

Exercise price $32.68 per share Conversion or exercise price of stock options

Underlying common shares 13,160 shares Common Stock underlying the option

Post-grant derivative holdings 13,160 options Total derivative shares following transaction

Option expiration May 27, 2036 Expiration date of the stock option grant

Key Terms

Non-Employee Director Compensation Program, stock option, vest, expiration date

4 terms

Non-Employee Director Compensation Program financial

"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program."

stock option financial

"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vest financial

"1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

expiration date financial

"expiration_date": "2036-05-27T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Tyra Biosciences (TYRA) report for Adele M. Gulfo?

Tyra Biosciences reported that director Adele M. Gulfo received a stock option grant for 13,160 shares of common stock. The options are compensation, not an open-market share purchase, and give her the right to buy shares at a fixed exercise price of $32.68.

What is the size and exercise price of Adele Gulfo’s stock option grant at Tyra Biosciences (TYRA)?

Adele Gulfo was granted options covering 13,160 shares of Tyra Biosciences common stock at an exercise price of $32.68 per share. This means she can buy those shares at $32.68 if and when the options vest and she chooses to exercise them.

How do Adele Gulfo’s Tyra Biosciences (TYRA) options vest over time?

One-twelfth of Adele Gulfo’s 13,160-share option vests monthly after the May 28, 2026 grant date. If the next annual shareholder meeting occurs before the one-year anniversary, any remaining unvested options vest at that meeting, assuming she remains in continuous service.

When do Adele Gulfo’s Tyra Biosciences (TYRA) stock options expire?

Adele Gulfo’s stock options are scheduled to expire on May 27, 2036. If unexercised by that date, the right to buy the 13,160 underlying common shares at the $32.68 exercise price will lapse and the options will no longer be usable.

Is Adele Gulfo’s Form 4 transaction in Tyra Biosciences (TYRA) a market purchase or a grant?

The Form 4 shows a grant of stock options to Adele Gulfo, not a market purchase of common shares. The options were awarded under Tyra Biosciences’ Non-Employee Director Compensation Program as equity-based compensation for her board service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gulfo Adele M.

(Last) (First) (Middle)

C/O TYRA BIOSCIENCES, INC.

2656 STATE STREET

(Street)

CARLSBAD CALIFORNIA 92008

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$32.68	05/28/2026		A		13,160		(1)	05/27/2036	Common Stock	13,160	$0	13,160	D

Explanation of Responses:

1. The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

	/s/ Ali D. Fawaz, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)